Cargando…

The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease

Accumulating evidence demonstrating higher cerebrospinal fluid (CSF) α-synuclein (αSyn) levels and αSyn pathology in the brains of Alzheimer’s disease (AD) patients suggests that αSyn is involved in the pathophysiology of AD. To investigate whether αSyn could be related to specific aspects of the pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Twohig, Daniel, Rodriguez-Vieitez, Elena, Sando, Sigrid B., Berge, Guro, Lauridsen, Camilla, Møller, Ina, Grøntvedt, Gøril R., Bråthen, Geir, Patra, Kalicharan, Bu, Guojun, Benzinger, Tammie L. S., Karch, Celeste M., Fagan, Anne, Morris, John C., Bateman, Randall J., Nordberg, Agneta, White, Linda R., Nielsen, Henrietta M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260771/ https://www.ncbi.nlm.nih.gov/pubmed/30477568 http://dx.doi.org/10.1186/s40478-018-0624-z

Ejemplares similares

Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer’s disease
por: Giannisis, Andreas, et al.
Publicado: (2022)

Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy controls: a two year follow-up study
por: Berge, Guro, et al.
Publicado: (2016)

The Amyloid, Tau, and Neurodegeneration (A/T/N) Classification Applied to a Clinical Research Cohort with Long-Term Follow-Up
por: Grøntvedt, Gøril Rolfseng, et al.
Publicado: (2020)

Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease
por: Patra, Kalicharan, et al.
Publicado: (2018)

Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer’s Disease, But Has Similar Diagnostic Accuracy to Aβ42
por: Lauridsen, Camilla, et al.
Publicado: (2017)

Cerebrospinal Fluid Levels of Amyloid Beta 1–43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer’s Disease: A 2-Year Follow-Up Study
por: Lauridsen, Camilla, et al.
Publicado: (2016)

Association of Klotho Protein Levels and KL-VS Heterozygosity With Alzheimer Disease and Amyloid and Tau Burden
por: Grøntvedt, Gøril Rolfseng, et al.
Publicado: (2022)

Predicting sporadic Alzheimer’s disease progression via inherited Alzheimer’s disease-informed machine-learning
por: Franzmeier, Nicolai, et al.
Publicado: (2020)

Incidence of Young Onset Dementia in Central Norway: A Population-Based Study
por: Kvello-Alme, Marte, et al.
Publicado: (2020)

The Prevalence and Subtypes of Young Onset Dementia in Central Norway: A Population-Based Study
por: Kvello-Alme, Marte, et al.
Publicado: (2019)

Time to Diagnosis in Young Onset Alzheimer’s Disease: A Population-Based Study from Central Norway
por: Kvello-Alme, Marte, et al.
Publicado: (2021)

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
por: Chiotis, Konstantinos, et al.
Publicado: (2023)

α-synuclein in the pathophysiology of Alzheimer’s disease
por: Twohig, Daniel, et al.
Publicado: (2019)

Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity
por: Sala, Arianna, et al.
Publicado: (2020)

Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer’s Disease
por: Almdahl, Ina S., et al.
Publicado: (2017)

Differentiating amyloid beta spread in autosomal dominant and sporadic Alzheimer’s disease
por: Levitis, Elizabeth, et al.
Publicado: (2022)

A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease
por: Almkvist, Ove, et al.
Publicado: (2023)

Discovery and validation of autosomal dominant Alzheimer’s disease mutations
por: Hsu, Simon, et al.
Publicado: (2018)

Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer’s disease
por: Salvadó, Gemma, et al.
Publicado: (2023)

Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer’s disease
por: Carter, Stephen F., et al.
Publicado: (2018)

Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding
por: Lemoine, Laetitia, et al.
Publicado: (2018)

Brain integrity is altered by hepatic APOE ε4 in humanized-liver mice
por: Giannisis, Andreas, et al.
Publicado: (2022)

Importance of CSF-based Aβ clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathways
por: Elbert, Donald L., et al.
Publicado: (2022)

Detecting At-Risk Alzheimer’s Disease Cases
por: Fladby, Tormod, et al.
Publicado: (2017)

Apolipoprotein E ε2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort
por: Berge, Guro, et al.
Publicado: (2014)

Clinical impact of (18)F-FDG-PET among memory clinic patients with uncertain diagnosis
por: Perini, Giulia, et al.
Publicado: (2020)

Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging
por: Murugan, N. Arul, et al.
Publicado: (2019)

Tau PET imaging: present and future directions
por: Saint-Aubert, Laure, et al.
Publicado: (2017)

Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease
por: Llorens, Franc, et al.
Publicado: (2017)

Data-driven models of dominantly-inherited Alzheimer’s disease progression
por: Oxtoby, Neil P, et al.
Publicado: (2018)

Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2018)

Tau PET imaging in neurodegenerative tauopathies—still a challenge
por: Leuzy, Antoine, et al.
Publicado: (2019)

GBA and APOE ε4 associate with sporadic dementia with Lewy bodies in European genome wide association study
por: Rongve, Arvid, et al.
Publicado: (2019)

Diurnal Patterns of Soluble Amyloid Precursor Protein Metabolites in the Human Central Nervous System
por: Dobrowolska, Justyna A., et al.
Publicado: (2014)

White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s disease
por: Araque Caballero, Miguel Ángel, et al.
Publicado: (2018)

Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease
por: Llibre-Guerra, Jorge J., et al.
Publicado: (2019)

Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study
por: Morenas-Rodríguez, Estrella, et al.
Publicado: (2022)

Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment
por: Chen, Charles D., et al.
Publicado: (2023)

Longitudinal clinical, cognitive and biomarker profiles in dominantly inherited versus sporadic early-onset Alzheimer’s disease
por: Llibre-Guerra, Jorge J, et al.
Publicado: (2023)

Author Correction: GBA and APOE ε4 associate with sporadic dementia with Lewy bodies in European genome wide association study
por: Rongve, Arvid, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hkbp4nm67ohr3vvi94hk1h532t